CholremCholesterol & arterial science

Company

Eight years ahead of a field that has just arrived

Cholrem was founded on the Gold Coast in 2018 on a single conviction: the molecule that dissolves cholesterol in a test tube should dissolve it in a human artery, and somebody had to find out. Cholrem found out.

Who we are

A research company with a product in people’s hands

Cholrem Pty Ltd is an Australian cardiovascular research and development company. It developed Cavadex®, a proprietary high-viscosity rectal formulation of pharmaceutical-grade HPβCD, and has studied its effect on human arteries continuously since 2018.

Unlike a conventional biotech, Cholrem did not wait for a trial to begin learning. Thousands of people have used its formulation since 2020, and the company built a member registry to capture their lipid panels, calcium scores, imaging and symptoms over years. That real-world engine is why Cholrem has human arterial data while the rest of the field has none.

Founder Kyle Hodgetts leads the research and is first author of every Cholrem paper.

  • Founded2018, Gold Coast, Queensland, Australia
  • FocusHPβCD therapy for cardiovascular and cholesterol-driven disease
  • Lead programCoronary atherosclerosis and calcification
  • PublicationsSix published human papers, one case report in peer review, one synthesis in preparation
  • Users4,000+ since 2020, worldwide
  • Intellectual propertyPatent pending on the high-viscosity formulation. Cavadex® registered trademark. Documented public prior art from 2019.
  • FounderKyle Hodgetts, lead researcher and first author

Timeline

From first infusion to a field

  • 2018

    Cholrem founded

    Established on the Gold Coast to test one question: can HPβCD regress human atherosclerosis?

  • 2019

    First human arterial imaging on HPβCD

    The founder’s coronary angiograms before and after 36 days of intravenous HPβCD show his right coronary narrowing reduced. Cholrem publicly discloses intravenous HPβCD in advanced atherosclerosis on its website. This disclosure predates every cardiovascular cyclodextrin patent filed since.

  • 2020

    Cavadex reaches the public

    The at-home rectal formulation launches. The delivery problem that stopped the rest of the field is solved in practice.

  • 2021

    Second intravenous study

    Carotid plaque reduced on ultrasound within weeks, with falls in cholesterol, triglycerides and liver markers.

  • 2024

    Independent clinical review

    The late Professor Laurie Howes reported on Cavadex. The 2019 and 2021 studies are published in Cardiology Research and Cardiovascular Medicine.

  • 2025

    Observational study and case series

    125-person quality-of-life study and a multi-territory plaque regression case series published.

  • 2026

    The field arrives

    Cholrem publishes high-viscosity case series and the first report of coronary calcification regressing. A three-vessel case report enters peer review. Beren wins FDA approval for HPβCD. Cyclarity receives FDA clearance for a cyclodextrin coronary trial. Patent filed on Cholrem’s formulation.

Founder

“Imagine discovering a treatment for the world’s number one killer.”

In 2019 Kyle Hodgetts had three stents, a right coronary artery narrowing again, and a life expectancy his cardiologist put at between six months and two and a half years. He gave himself intravenous HPβCD for 36 days. Repeat angiography showed the narrowing reduced, and his cardiologist’s advice changed from another stent to medical management. He then set out to make the molecule work at home. Seven years on he still leads the company, and has taken more Cavadex than anyone.

Kyle Hodgetts began with a molecule, a hypothesis and the willingness to test it on himself. Eight years, seven papers and thousands of users later, the hypothesis has human images behind it and the world’s biotech industry has arrived at the same molecule. The Cholrem story is one of persistence against a system built for a different kind of company.